8-K: Mineralys Therapeutics Announces Positive Topline Results from Lorundrostat Phase 3 and Phase 2 Trials for Uncontrolled and Resistant Hypertension

Mineralys Therapeutics reports positive topline data from its Launch-HTN Phase 3 and Advance-HTN Phase 2 trials, indicating lorundrostat's efficacy and safety in treating uncontrolled and resistant hypertension.

Summary

• Mineralys Therapeutics announced positive topline data from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials.
• Both trials evaluated the efficacy and safety of lorundrostat for treating uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
• The Launch-HTN trial, a global, randomized, double-blinded, placebo-controlled Phase 3 trial, enrolled adult participants who failed to achieve their blood pressure goal despite being on two to five antihypertensive medications.
• The Launch-HTN trial met its endpoints, demonstrating a statistically significant mean reduction from baseline in placebo-adjusted systolic blood pressure at week six and week 12.
• At week 6, the 50 mg dose achieved a 9.1 mmHg placebo-adjusted reduction (p<0.0001), and at week 12, an 11.7 mmHg placebo-adjusted reduction (p<0.0001).
• The Advance-HTN trial, a randomized, double-blind, placebo-controlled Phase 2 pivotal trial, evaluated the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN.
• The Advance-HTN trial met its primary endpoint, with a placebo-adjusted reduction from baseline in systolic blood pressure of -7.9 mmHg at week 12 in subjects treated with 50 mg of lorundrostat.
• The company believes clinical safety findings from both trials support a favorable benefit-risk profile.
• The ongoing Transform-HTN open-label extension trial allows subjects to continue to receive lorundrostat and generate additional safety and efficacy data.

Sentiment

Score: 8

Explanation: The document presents positive topline results from clinical trials, indicating potential for a new treatment option for hypertension, which is generally viewed favorably.

Positives

• Both the Launch-HTN and Advance-HTN trials achieved their primary endpoints, demonstrating statistically significant and clinically meaningful reductions in blood pressure.
• Lorundrostat showed a favorable safety and tolerability profile in both trials.
• The Launch-HTN trial reflects a real-world setting by utilizing automated office blood pressure (AOBP) measurement and allowing participants to stay on their existing medications.
• The company believes the results support the potential regulatory approval of lorundrostat.
• The ongoing Transform-HTN open-label extension trial will generate additional safety and efficacy data.

Negatives

• The incidence of hyperkalemia (serum potassium above 6.0 mmol/L) was observed in both the Launch-HTN and Advance-HTN trials, with higher rates in the Advance-HTN trial (5.3% and 7.4%).
• There were treatment-emergent serious adverse events (SAEs) reported in the Launch-HTN trial, although the rates were generally comparable to or lower than the placebo arm.

Risks

• Topline results are based on preliminary analysis and may change following a more comprehensive review.
• The company's future performance is dependent entirely on the success of lorundrostat.
• Potential delays in clinical trials and nonclinical studies could impact timelines.
• The FDA may not deem the results sufficient for NDA submission or regulatory approval.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat could limit its development and commercialization.
• The company relies on its exclusive license with Mitsubishi Tanabe Pharma for intellectual property rights.

Future Outlook

The company plans to provide additional data from the two pivotal trials at upcoming medical conferences and in peer-reviewed publications and will continue the Transform-HTN open-label extension trial.

Management Comments

• Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, stated that lorundrostat has the potential to be a transformative new therapy for patients with uncontrolled hypertension.
• Manish Saxena MBBS, Hypertension Specialist from Barts Health NHS Trust, stated that lorundrostat could be a good treatment option for millions of patients with high blood pressure.

Industry Context

The announcement addresses the significant unmet need in hypertension treatment, as less than 50% of hypertension patients achieve their blood pressure goal with currently available medications, and dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

Comparison to Industry Standards

• The Launch-HTN study is described as one of the largest blood pressure studies in recent times, suggesting a significant investment and scope compared to other trials in the field.
• The reported placebo-adjusted reductions in systolic blood pressure in both trials are clinically meaningful and potentially competitive with existing hypertension treatments.
• Further comparison would require detailed analysis against specific competitor drugs and their clinical trial results, such as those from companies like Novartis (Entresto for heart failure with hypertension) or AstraZeneca (various hypertension medications).

Stakeholder Impact

• Shareholders may react positively to the positive trial results.
• Patients with uncontrolled or resistant hypertension may benefit from a new treatment option.
• Clinical investigators and site staff involved in the trials are acknowledged for their commitment and hard work.

Next Steps

• Mineralys plans to provide additional data from these two pivotal trials at upcoming medical conferences and in peer-reviewed publications.
• The ongoing Transform-HTN open-label extension trial allows subjects to continue to receive lorundrostat and generate additional safety and efficacy data.
• The company may submit a new drug application (NDA) to the United States Food and Drug Administration (FDA).

Key Dates